BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dr. Reddy's Laboratories readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Dr. Reddy's Laboratories's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06015048-2207@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT06015048)
DESCRIPTION:Pyrotinib\, phase 1/2.\nStudy: A Trial of SHR-A1811 Combined Wi
 th Other Antitumor Therapies in Advanced Solid Tumors.\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06015048
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-2207@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Pyrotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A T
 rial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in 
 Subjects With Advanced Non-small Cell Lung Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05482568
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980054-2207@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT03980054)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: A Study of Evaluating The Effects 
 Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast C
 ancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03980054
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895512-3168@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HLX15: Phase 3 readout est. (NCT06895512)
DESCRIPTION:HLX15\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evaluate
  the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with
  Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/hlx15#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06895512
URL:https://assetmemo.bio/drug/hlx15#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161974-2857@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06161974)
DESCRIPTION:Olutasidenib\, phase 2\, Glioma.\nStudy: Study of Olutasidenib 
 and Temozolomide in HGG\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06161974
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604064-2857@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07604064)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Clin
 ical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07604064
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
